Canada markets closed

Relay Medical Corp. (RYMDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2539+0.0184 (+7.83%)
At close: 3:27PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2355
Open0.2400
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2395 - 0.2614
52 Week Range0.1980 - 0.7240
Volume59,211
Avg. Volume131,400
Market Cap38.631M
Beta (5Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.0520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    NEXT SUPER STOCKS on The Move: Tetra Bio-Pharma, Relay Medical, Victory Square Technologies, and Red Light Holland

    “Unicorn Farms”, Psychedelics, Pharma Innovation, and HealthTech...NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “LiveChats” on social media streams. Over 170,000 investors have participated in Wall Street Reporter’s livestream events in the past 30 days. Victory Square Technologies (OTC: VSQTF) (CSE: VST) CEO, Shafin Diamond Tejani: “‘Unicorn Farm’ with Multiple Shots on Goal”In a recent presentation at Wall Street Reporter’s NEXT SUPER STOCK livestream, Victory Square Technologies (OTC: VSQTF) (CSE: VST) CEO, Shafin Diamond Tejani shared VSQTF’s growth strategy for investing and developing disruptive technology companies - which can have “unicorn”/billion dollar valuation potential. VSQTF’s portfolio consists of over 20 companies in sectors such as HealthTech, E-Sports, AI, VR/AR, Blockchain, Fintech and other emerging sectors. Watch Victory Square Technologies (OTC: VSQTF) NEXT SUPER STOCK Video: https://bit.ly/3vNlROv Shafin shares the view that VSQTF’s portfolio is a “Unicorn farm” with “multiple shots on goal” for achieving billion dollar wins. One of VSQTF’s recent success stories is FansUnite (FANS) the iGaming/esports betting company, which was spun off last year, and recently trading at $100 million+ valuation. Shafin explained how VSQTF will be spinning-off more exciting companies in the coming months, in the gaming and AR sectors and creating shareholder value. May 4 - VSQTF Reports record Net Income of C$19,733,031 - C$0.30 per share for FY 2020 Watch Victory Square Technologies (OTC: VSQTF) NEXT SUPER STOCK Video: https://bit.ly/3vNlROv Tetra Bio-Pharma (OTC: TBPMF) (TSX: TBP) CEO, Dr. Guy Chamberland: “Expecting to Launch 3 New Cannabinoid-Derived Drugs in 2022 - Addressing $200 Billion Market Opportunities” In a recent presentation at Wall Street Reporter’s NEXT SUPER STOCK livestream, Tetra BioPharma (OTC: TBPMF) CEO, Dr. Guy Chamberland shared TBPMF’s advanced pipeline of cannabinoid derived drugs targeting $200 billion addressable market opportunities including pain, inflammation, oncology, and sepsis. TBPMF boasts one of the most advanced pipelines of Cannabinoid-derived medicines, supported by the urgent need for non-opioid alternatives to treat pain and inflammation. Significantly, TBPMF’s portfolio of IP and patents is spearheaded by a team experienced at bringing new drugs to market. TBPMF now has 3 drugs in the advanced clinical stages, which it expects to bring to market in 2022: Quixleef targeting pain management, a $58 billion market opportunity, ARDS-003 immunomodulator which is a $132 billion market opportunity, and PPP-003 for ophthalmic inflammation indication - a $31 billion market. Compelling for investors, TBMPF has multiple near-term catalysts in place, and with a current valuation of about $50 million, TBPMF is trading at a just a small fraction of its peer group in the biotech space, with similar pipelines. Watch Tetra Bio-Pharma (OTC: TBPMF) Next Super Stock video: https://bit.ly/2QzBElc May 6 - TBPMF Announces start of REBORN1© clinical trial. This trial is designed to evaluate the effect of the Company's inhaled proprietary drug formulation, QIXLEEF™, against immediate release oral morphine sulfate on onset of pain relief in people living with cancer. QIXLEEF™ is a botanical drug product with a "fixed ratio" of THC and CBD and is inhaled through a Class 2 medical device vaporizer. REBORN1© is being conducted in the United States in collaboration with the Hassman Research Institute, a clinical research organization, who will enroll twenty adults living with breakthrough cancer pain (BTcP) and currently taking stable opioid treatment for breakthrough pain. This innovative Phase 2 pilot, proof-of-concept open-label crossover comparison study will assess whether inhaled QIXLEEF™ will control BTcP faster than immediate-release morphine sulfate tablets. May 5 - TBPMF signs C$46 Million deal with DanCann Pharma A/S for the exclusive distribution of Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany. Subject to registration with the European Medicines Agency (EMA), DanCann Pharma will handle the exclusive sales and distribution in the Nordics and Germany for Reduvo™ Adversa® and QIXLEEF™, a botanical cannabinoid-derived medicine, as well as Tetra's medicinal cannabis product ENJOUCA™. The Agreement encompasses a sum of upfront and milestone payments of up to $1,5M CAD, and expected cumulative royalties in excess of $46M CAD on DanCann's cumulative sales for Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ from 2021 to 2028. May 3 - TBPMF receives Health Canada Drug Establishment License (DEL) to distribute REDUVO soft gel capsules in Canada - addressing $80 million market opportunity in Canada. REDUVO is a synthetic THC-based soft gel capsule indicated in severe nausea and vomiting associated with cancer chemotherapy. REDUVO is currently being assessed by Health Canada for the issuance of a Drug Identification Number (DIN). REDUVO, known as Marinol in the United States, has been approved as a regulated pharmaceutical drug by the U.S. Food and Drug Administration since 1985. Watch Tetra Bio-Pharma (OTC: TBPMF) Next Super Stock video: https://bit.ly/2QzBElc Relay Medical (CSE: RELA) (OTC: RYMDF) President Clark Kent: “AI Diagnostics Targeting Billion Dollar Healthcare Opportunities” In a recent presentation at Wall Street Reporter’s Investors Discovery Day livestream, Relay Medical Corp. (CSE: RELA) (OTC: RYMDF) President Clark Kent, discussed the company’s diagnostics and AI HealthTech focus, which targets multi-billion dollar opportunities in global healthcare markets. A highlight of the presentation was a video demo of the company’s rapid testing and tracking platform for infectious diseases, including COVID-19. The platform has already been successfully deployed in testing and tracking infectious disease outbreaks globally, including ebola and malaria. Watch Relay Medical (OTC: RYMDF) Investors Discovery Day Video: http://bit.ly/3aRwEzn May 6 - RYMDF reports on success of its COVID rapid testing solution at Toronto Pearson International Airport. The Greater Toronto Airports Authority (GTAA), operator of Toronto Pearson, and FRR (Fionet Rapid Response - a joint venture of RYMDF and and Fio Corporation) worked closely to create a first-of-its-kind biosecurity testing capability at the airport, which has produced outstanding results in its first full month of operation. FRR’s Platform Tested 8,000 People, with an average 30-Minute turnaround. The Fionet Platform (“Fionet”) performed antigen testing for 8,000 people, including airport employees and internationally departing passengers. Airlines flown included: AeroMéxico, Air Canada, Air France, Air India, American, Avianca, British Airways, Caribbean Airlines, Copa Airlines, Cathay Pacific, Delta, El Al, EVA Air, Egyptair, Emirates, Ethiopian Airlines, Etihad, KLM, Korean Air, LOT Polish Airlines, Lufthansa, Philippine Airlines, TAP Air Portugal, Turkish Airlines, United, and WestJet.Fionet’s innovations include replicable assembly lines that can be parallelized. Five Fionet devices, each doing 60 tests/hour, can clear 300 passengers/hour - e.g., a Boeing 737 or an Airbus A310. Watch Relay Medical (OTC: RYMDF) Investors Discovery Day Video: http://bit.ly/3aRwEzn Red Light Holland (OTC: TRUFF) (CSE: TRIP) CEO Todd Shapiro: ”Psychedelics is Next Billion Dollar Market Opportunity” In a recent presentation on Wall Street Reporter’s NEXT SUPER STOCK livestream, Red Light Holland (OTC: TRUFF) (CSE: TRIP), CEO Todd Shapiro updated investors on the TRUFF’s latest market expansion and success in the psychedelics sector, and major new growth opportunities in coming months. TRUFF produces and sells recreational grade psychedelic Magic Truffles to the current legal adult use market in the Netherlands, and is planning global expansion as legislation is rapidly changing globally. TRUFF: “The Tesla of Psychedelics” Todd was joined by cannabis industry pioneer and TRUFF advisory board chairman, Bruce Linton who shared his perspective on TRUFF’s growth opportunities. Also joining the livestream was TRUFF CTO Sarah Hashkes who shared the company’s unique technology-driven marketing and branding strategy for psychedelics, which has been likened by some investors as the “Tesla of Psychedelics” Watch (OTC: TRUFF) Next Super Stock livestream Video: https://bit.ly/3u4aGR4 April 21 - TRUFF announces increase of Points of Sale for its iMicrodose Packs in the Netherlands by More Than 140% - $31 million cash on hand to fund growth. TRUFF CEO Todd Shapiro commented: "Over the last few months, we have continued executing on our goal to increase both the availability of our products and our brand's visibility. iMicrodose Packs powered by Red Light Holland are now available in 144% more locations than previously announced. Relationships held by our wholly owned distribution company SR Wholesale, already, account for 13 new locations, demonstrating some of the synergies that we strategically planned to realize from the recently closed acquisition. With over $31 million of cash and cash equivalents remaining on our balance sheet, we look forward to continuing to conservatively deploy capital into growth opportunities that support our long-term business objectives March 19 - TRUFF closes acquisition of SR Wholesale B.V., one of the Netherlands' premiere distributors for quality psychedelic truffles. In 2020, SR Wholesale generated over C$2.44 Million in revenues, and over $822,0001 in gross profit, with approximately $400,0001 of cash and working capital currently on hand. SR Wholesale has established a distribution network of over 400 companies that sell their products across Europe, including working with sub-distributors which provide products to over 1,000 shops in countries like the Netherlands, Germany, Spain, Czech, Greece, UK, France, and Portugal. Watch (OTC: TRUFF) Next Super Stock Video: https://bit.ly/3u4aGR4 WALL STREET REPORTER Wall Street Reporter (Est. 1843) is the leading financial news provider, focused on giving investors direct access to CEO's of promising, publicly-traded companies, and market experts. www.WallStreetReporter.com. Nothing in this news summary shall be construed as investment advice. Quotes/content may be edited for brevity and context. Full disclaimer, and relevant SEC 17B disclosures here: http://bit.ly/39kkE7K About Wall Street Reporter’s Next Super Stock conference: Wall Street Reporter's NEXT SUPER STOCK Live! conference is dedicated to featuring select companies that have near-term catalysts in place which can drive transformational growth (and stock appreciation) in the months ahead. Click here to join next livestream event: https://www.wallstreetreporter.com/next-superstock-online-investor-conference/ CONTACT: WALL STREET REPORTER (212) 871-2057 ext 7 www.WallStreetReporter.com

  • Relay Medical and Fio Report on Testing Success at Pearson Airport and the Significance of What Has Been Accomplished
    GlobeNewswire

    Relay Medical and Fio Report on Testing Success at Pearson Airport and the Significance of What Has Been Accomplished

    Fionet High-throughput Assembly Line Fionet’s innovations include replicable assembly lines that can be parallelized. Five Fionet devices, each doing 60 tests/hour, can clear 300 passengers/hour - e.g., a Boeing 737 or an Airbus A310. All modules of Fionet deployed at Toronto Pearson (1) Fionet Manager does browser-based registration, scheduling, reporting; (2) Fionet Deki Devices do rapid diagnostic tests (RDT); (3) Fionet Broker connects diagnostic devices, databases, lab information systems; (4) Fionet Portal does reporting; (5) Fionet Cloud does AI-based real-time analytics, quality control, and system management. TORONTO, May 06, 2021 (GLOBE NEWSWIRE) -- Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) and Fio Corporation (“Fio”), through their joint venture company Fionet Rapid Response Group (“FRR”), report on successful, unprecedented on-site testing at Toronto Pearson International Airport (“Toronto Pearson”). The Greater Toronto Airports Authority (GTAA), operator of Toronto Pearson, and FRR worked closely to create a first-of-its-kind biosecurity testing capability at the airport, which has produced outstanding results in its first full month of operation. FRR’s Platform Tested 8,000 People, with an average 30-Minute turnaround The Fionet Platform (“Fionet”) performed antigen testing for 8,000 people, including airport employees and internationally departing passengers. Airlines flown included: AeroMéxico, Air Canada, Air France, Air India, American, Avianca, British Airways, Caribbean Airlines, Copa Airlines, Cathay Pacific, Delta, El Al, EVA Air, Egyptair, Emirates, Ethiopian Airlines, Etihad, KLM, Korean Air, LOT Polish Airlines, Lufthansa, Philippine Airlines, TAP Air Portugal, Turkish Airlines, United, and WestJet. Fionet’s innovations include replicable assembly lines that can be parallelized. Five Fionet devices, each doing 60 tests/hour, can clear 300 passengers/hour - e.g., a Boeing 737 or an Airbus A310. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/50f6be7c-6534-4745-b2f3-2e9e3dc77de8 GTAA deployed Fionet Platform for all parts of its biosecurity testing process GTAA selected Fionet not only for testing, but also for integrating the complex processes of testing, reporting, and passenger logistics. All modules of Fionet Platform are deployed at Toronto Pearson: (1) Fionet Manager does browser-based registration, scheduling, reporting; (2) Fionet Deki Devices do rapid diagnostic tests (RDT); (3) Fionet Broker connects diagnostic devices, databases, lab information systems; (4) Fionet Portal does reporting; (5) Fionet Cloud does AI-based real-time analytics, quality control, and system management. A graphic accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/94752779-4322-46e5-8078-657d434bd7a2 In recognition of contributions by FRR’s CTO, he was profiled as last month’s “Person of Pearson”:https://www.torontopearson.com/en/whats-happening/stories/people-of-pearson/2021-04-07-ian. “With 9/11, airports stepped up to ensure safety and enable a knocked-down economy get upright again. With COVID, Toronto Pearson stepped up again to the same thing. We are inspired by their vision, commitment, and execution to set a new standard in biosecurity,” said Ian Fine, FRR’s CTO. “After successfully installing on-site rapid antigen testing at Toronto Pearson, we are now launching an additional PCR testing capability in our on-site Biosecurity Lab. These advancements are driven by Toronto Pearson’s award-winning Healthy Airport commitment, which includes the promise to use any innovative technology if it can protect our community. FRR and the Fionet Platform have been instrumental in that protection, advancing biosecurity defences at the airport, which benefit passengers, airlines, airport workers and the residential areas that neighbour Pearson,” said Dwayne Macintosh, Director, Corporate Safety and Security. “Decentralized mass testing in community settings - where people travel, work, study, play, and live - requires testing platforms with an optimal balance of speed and accuracy. Whereas many other types of devices do one test per hour, Fionet does one test per minute. To do one million tests in a month, that is a comparison between one million machine hours and 17,000 machine hours, which is a comparison between never going to happen and entirely doable. On top of which, Fionet’s AI-algorithms provide continuously running, proven accuracy checks,” said Dr Michael Greenberg, CEO of FRR and CEO of Fio Corporation. “FRR is an extraordinarily productive joint venture between Relay Medical and Fio Corporation. In a short time and while still coming into our stride, FRR has made leap after leap in material business accomplishments. Every accomplishment multiplies new opportunities. We are excited to realize the full benefit of the value that our work is creating,” said Yoav Raiter, CEO of Relay Medical. About GTAA The Greater Toronto Airports Authority (GTAA) is the operator of Toronto Pearson International Airport. Toronto Pearson served more than 50 million passengers in 2019, making it Canada’s busiest airport. Website: www.torontopearson.com About Fionet The Fionet Platform is an end-to-end, rapid testing and tracking solution for community-based or decentralized settings. Combining a fast, handheld point-of-need device connected in real time to cloud data services, the Fionet Platform handles scheduling and registration via phone app at home, on-site check-in, rapid, on-the-spot antigen testing, data integration with other testing devices, result notification, public health notification as appropriate, and anonymized data and stats for dashboards for authorized stakeholders. Website: www.fionetrapidresponse.com About Relay Medical Corp. Relay Medical is a technology innovation company headquartered in Toronto, Ontario, with a team of Canadian experts focused on the development of novel technologies in the diagnostics, AI data science sectors, and IoT cybersecurity sectors. Website: www.relaymedical.com About Fio Corporation Fio Corporation, privately held and headquartered in Toronto, developed and markets the world’s first integrated guidance & tracking IT platform for decentralized healthcare settings, a new category of solution that raises healthcare quality and lowers healthcare costs. The platform enables average healthcare workers in clinics to deliver a new level of quality-controlled diagnostic testing and case management. Website: www.fionetrapidresponse.com For Media Inquiries, please contact: Destine Lee media@relaymedical.com | 647-872-9982 Subscribe: For further information on Relay Medical or to subscribe to the mailing list, please visit: https://www.relaymedical.com/news Contact:W. Clark KentPresidentRelay Medical Corp.Office. 647-872-9982 ext. 2TF. 1-844-247-6633 ext. 2investor.relations@relaymedical.com Bernhard LangerEU Investor RelationsOffice. +49 (0) 177 774 2314Email: blanger@relaymedical.com Forward-looking Information Cautionary Statement Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, for which filings are available at www.sedar.com.

  • Emerging Markets Report: Rapid and Real Time
    GlobeNewswire

    Emerging Markets Report: Rapid and Real Time

    An Emerging Markets Sponsored Commentary ORLANDO, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Allow us to introduce Relay Medical Corp. (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2). The Company is a technology innovation company headquartered in Toronto, Ontario, with a team of Canadian experts focused on the development of novel technologies in the diagnostics, AI data science sectors, and IoT cybersecurity sectors. Relay Medical announced on April 14, 2021 that together in conjunction with Fio Corporation and Fio’s joint venture company, Fionet Rapid Response Group, an agreement with LifeLabs was completed, to deploy the Fionet Platform for COVID-19 rapid testing and real-time tracking across Canada, and will be used to launch the Company’s platform to support COVID-19 testing at Canada’s largest international airport Pearson International. For those south of the Canadian border, LifeLabs is Canada’s largest provider of specialty laboratory testing services, laboratory diagnostic information and digital health connectivity systems. For Relay Medical, this is a major partner who can introduce this technology far and wide. LifeLabs supports 20 million patient visits annually and conducts over 100 million laboratory tests through leading edge technologies and its 6,000 employees. It’s a massive footprint. And it’s much needed. A quote from Dr. Greenberg who is the CEO of Fionet Rapid Response, says it best. “COVID-19’s threat to personal and economic well-being across the country created a need for innovation in technology and service. Through this alliance, LifeLabs and FRR are bringing into any community setting the caliber of automated, quality-controlled testing and tracking that previously was available only in centralized lab facilities.” And that’s what’s significant here in our estimation… that FRR can bring this fast, accurate testing to any community directly, instead of compelling them to go to a lab and wait to find out results.Now, LifeLabs will provide the Fionet Platform in community-based settings at multiple sites across Canada, including airports, pop-up labs, and installations for small businesses. The business opportunity on top of this public service is that each Fionet device can process 60 tests an hour and provide results within 15 minutes, on a fee per test basis. There is both a massive need and a massive opportunity in the offering which provides rapid results in real time. About The Emerging Markets Report: The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets. For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php Must Read OTC Markets/SEC policy on stock promotion and investor protection https://www.otcmarkets.com/learn/policy-on-stock-promotionhttps://www.otcmarkets.com/learn/investor-protectionhttps://www.sec.gov/news/press-release/2017-79https://www.sec.gov/oiea/investor-alerts-bulletins/ia_promotions.html Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below. We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies. EMC has been paid $175,000 by Relay Medical Corp. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php Emerging Markets Consulting, LLCFlorida Office390 North Orange Ave Suite 2300Orlando, FL 32801E-mail: jamespainter@emergingmarketsllc.comWeb: www.emergingmarketsllc.com